ArticleJHEP reports : innovation in hepatology2026
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) are rising causes of liver-related morbidity and mortality worldwide. The burden among women of childbearing age (15-49 years) is not well defined. We quantified global and regional trends from 2010 to 2021 and projected prevalence through 2035. Methods: Prevalence, incident cases, and disability-adjusted life-years (DALYs) among women of childbearing age were estimated using the Global Burden of Disease 2021 framework. Temporal trends were evaluated using Joinpoint regression to estimate annual percent change. Inequality was assessed using the slope and concentration indices, and prevalence was projected using Bayesian age-period-cohort models. Results: Between 2010 and 2021, global MASLD prevalence rose by 13.8%, reaching 15,759 per 100,000 population in 2021. The highest burden was observed in the Eastern Mediterranean region (24,530 per 100,000 population), with the most pronounced increases seen in high sociodemographic index countries (+20.0%) and the Western Pacific region (+21.9%). Conversely, ALD prevalence declined by 6.8% to 11.0 per 100,000 population, with notable declines in Europe (-15.5%) but modest increases in the Western Pacific (+10.5%) and Eastern Mediterranean (+3.7%). The burden of both MASLD and ALD rose steadily with age and peaked among women aged 45-49 years. Despite a higher prevalence, MASLD contributed modest DALY rates (20.4 per 100,000 population), whereas ALD, although less prevalent, imposed a greater burden (29.1 per 100,000 population). By 2035, MASLD prevalence is projected to reach 17,393 per 100,000 population (+10.4%), and ALD prevalence is projected to reach 11.5 per 100,000 population (+4.5%). Conclusions: MASLD is rapidly increasing among women of childbearing age, with marked regional and socioeconomic disparities, whereas the burden of ALD appears to be in decline. Impact and implications: Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) among women of childbearing age are often overlooked despite significant maternal and intergenerational health consequences. Our analysis shows a rising prevalence of MASLD and a modest decline in ALD, with marked regional and socioeconomic disparities, and projects continued MASLD growth through 2035. These findings are important for clinicians, researchers, and policymakers, given the associated maternal, neonatal, and intergenerational risks. Integrating metabolic and reproductive health services alongside equitable policy interventions may help mitigate these concerning trends.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.